ALS (ASX: ALQ) – ALQ Half Year 2026 Results

ALS Limited reported underlying earnings per share growth of 23.6% to $214.6 million for the half year ending 30 September 2026, underpinned by organic revenue expansion of 10.2%. The company’s underlying earnings before interest and tax climbed 18.6% to $332.7 million, with the group operating margin expanding 250 basis points to 19.4%. This performance reflects broad strength across its diversified testing, inspection and certification platform, though results mask significant divergence between its two operating divisions.

The Commodities division, which comprises the Minerals and Industrial Materials businesses, delivered particularly strong results with revenue up 20.4% to $737.2 million. Underlying earnings before interest and tax margin expanded 371 basis points to 31.6%, driven by robust organic growth of 10.2% and disciplined pricing. Within Commodities, Minerals delivered organic growth of 30.4% supported by strong sample volumes and pricing discipline as elevated exploration activity continues. The company notes that mining majors and mid-tier operators are maintaining investment in resource expansion programs, while junior financing conditions have improved notably. Industrial Materials grew organically by 3.0%, though Oil and Lubricants showed a minor 1.1% decline reflecting temporary supply constraints in the United States that the company expects to ease.

Life Sciences proved more challenging, with revenue declining 6.6% to $978 million on a reported basis, though organic growth of 1.8% suggests underlying demand resilience. The division’s underlying earnings before interest and tax margin compressed 95 basis points to 13.7%, reflecting lower volumes in the Pharma business where activity levels remain subdued. Environmental grew 2.1% organically despite quality issues in the Americas that management has now addressed, while Food division delivered solid 6.8% organic growth, the fourth consecutive year of expansion. Pharma represents the key headwind, with organic revenue declining 4.1% as the Nuvisan acquisition continues to work through capacity utilization challenges.

The company’s balance sheet remains robust with net leverage at 1.5 times adjusted underlying earnings before interest, tax, depreciation and amortisation, well below management’s target range of 1.7 to 2.3 times. Free cash flow before capital expenditure increased 7.6% to $327.1 million, though underlying earnings before interest, tax, depreciation and amortisation cash conversion dipped to 82.4% from 88.0% as inventory levels rose to manage supply chain risks from Middle East disruptions. The company declared an interim dividend of 23.3 cents per share, partially franked at 35%, representing a 20.1% increase on the prior period.

A rules-based approach to leveraged ETFs

See how our quantitative strategy works and who it suits.

Explore the strategy

Become an authorised representative

Advise your clients under an established AFSL without building your own. Choose AR or CAR.

Become an AR or CAR

For the full year, management targets high single digit organic revenue growth on a constant currency basis with ongoing margin expansion. Within Commodities, management expects around 20% organic revenue growth for the Minerals business in FY27 on a constant currency basis, with a further 20 to 30 basis points of margin improvement anticipated in the second half. Life Sciences is expected to return to mid single digit organic growth, though foreign exchange headwinds are forecast to impact underlying earnings before interest and tax and underlying net profit after tax by an estimated $3.5 million and $2.5 million respectively per percentage point of adverse currency movement. This announcement is price sensitive and has been flagged as material by the ASX.

View the full ASX announcement (PDF)

About ALS Limited (ASX: ALQ)

ALS Limited is a global leader in laboratory testing, inspection, certification, and verification services, operating from approximately 350 sites across 65 countries. The company operates two main divisions: Commodities, which provides assaying and metallurgical services for the mining sector, and Life Sciences, which offers analytical testing for environmental, food, pharmaceutical, and consumer products markets. Headquartered in Brisbane, Australia, ALS serves major clients across Africa, Asia Pacific, Europe, the Middle East, North Africa, and the United States.

Learn to trade with a plan

Our free 5-day course covers entries, exits and risk management.

Become an authorised representative

Advise your clients under an established AFSL without building your own. Choose AR or CAR.

Become an AR or CAR

This is general advice only. MF & Co Asset Management has not considered your personal financial needs, objectives or current situation. This information is not an offer, solicitation, or a recommendation for any financial product unless expressly stated. You should seek professional investment advice before making any investment decision.

You May Also Like…

« Older Entries

Unlock every article for free

Become an authorised representative

Advise your clients under an established AFSL without building your own. Choose AR or CAR.

Become an AR or CAR

MF & Co. Asset Management

MF & Co. Asset Management is a boutique investment firm offering Equity Capital Markets and derivative general advice & trade execution services.

We are specialists in advising and trading in Australian and US Equities, Index & Equity Options and Options on Futures.